Track Record

Our partners and licensees have succeeded in bringing DPI, pMDI and nebuliser medicines to market with the help of our specialist capabilities.

1. Registered trade marks of Novartis AG 2. Registered trademarks of Novartis AG 3. flutiform® is a registered trade mark of Jagotec AG (in some territories, owned by Mundipharma AG). K-haler® is a registered trade mark of Mundipharma AG. 4. Breelib™ is a registered trade mark of Bayer Intellectual Property GmbH 5. Registered trade marks of Glaxo Group Ltd. Formulation technology licence, product not developed by Vectura. 6. Evaluate Pharma; internal estimates

SANDOZ

Formulation + device + development 1

Novartis

Formulation 2

MUNDIPHARMA, KYORIN

Formulation + device + development 3

Bayer

Formulation + device + development 4

GSK

Formulation 5

Our combination of formulation science, device technology and inhaled development expertise has contributed to the success of 11 inhaled medicines, launched by our partners and licensees. Since launch, they have generated $10 billion in sales and in 2018 these products were used by 9 million patients worldwide6

 

$10bn

sales since launch

9m

patients treated worldwide

1. Registered trade marks of Novartis AG 2. Registered trademarks of Novartis AG 3. flutiform® is a registered trade mark of Jagotec AG (in some territories, owned by Mundipharma AG). K-haler® is a registered trade mark of Mundipharma AG. 4. Breelib™ is a registered trade mark of Bayer Intellectual Property GmbH 5. Registered trade marks of Glaxo Group Ltd. Formulation technology licence, product not developed by Vectura. 6. Evaluate Pharma; internal estimates